$KPLT

Director at Katapult (KPLT) awarded 20,979 DSUs for board service

Katapult Holdings director Donald Gayhardt was granted 20,979 deferred stock units (DSUs) as compensation for his board service. The grant is valued at $7.15 per share and will vest on the earlier of April 30, 2027, or the company's 2027 Annual Meeting of Stockholders, contingent on his continued directorship. Following this award, Gayhardt directly holds 62,460 shares of Common Stock in Katapult.

Original reporting
Published May 5, 2026, 1:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 5, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$KPLT
Bullish
medium confidence
Mentioned
$KPLT
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$KPLTBullishMed
01

Why it matters

While indicative of management confidence, this event alone does not guarantee stock performance changes but may influence investor sentiment.

02

Market read

The news is directly relevant to KPLT shareholders and potential investors, with moderate impact expected on stock sentiment.

03

What to watch

External market conditions, overall company performance, and broader economic indicators could overshadow this insider activity.

Timing: Immediate, as the news was published today.

Background

The news reports a director's grant of DSUs, a form of deferred stock compensation, which is common in corporate governance and executive compensation practices.

Company-level read

Ticker impact

$KPLTBullishMedium confidence
Context

The news pertains directly to the company's insider stock activity, indicating internal recognition and potential future performance implications.

Expected impact

Moderate upward movement in the short term, contingent on broader market conditions.

Evidence & confidence

Insider grants often reflect management's confidence; however, the impact depends on overall market sentiment and external factors.

Market effects

Potential positive sentiment within the finance and corporate governance sectors.

Limited, as the news pertains specifically to a U.S.-listed company.

Minimal, unless the company is a significant industry player.

Counterpoint

The insider grant could be a routine compensation event with limited market impact, and the stock may not experience significant price movement.

Key entities

  • Katapult Holdings

    A company involved in the finance sector, with recent insider stock activity.

Related articles

$KPLTLow

Katapult Holdings, Inc. (KPLT): Completion of Acquisition or Disposition of Assets

Katapult Holdings, Inc. (KPLT) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Exhibit 99.1 Confidential Katapult, The Aaron’s Company, and CCF Holdings Complete Business Combination to Create a Scaled Financial Solutions Platform for Nonprime Consumers Scaled Omnichannel Platform Expands Opportunities to Reach More Consumers Through Complementary Retail, D

$KPLTMedAI 9/10

Katapult Holdings, Inc.: Katapult, The Aaron's Company, and CCF Holdings Complete Business Combination to Create a Scaled Financial Solutions Platform for Nonprime Consumers

Katapult Holdings (NASDAQ: KPLT) said it completed an all-stock business combination with The Aaron’s Company and CCF Holdings, creating a scaled financial solutions platform for nonprime consumers. The combined company will operate under the Katapult Holdings name and keep trading as KPLT. Pro forma 2025 revenue was over $4bn and adjusted EBITDA over $460mn.

$KPLTMed

Katapult Holdings, Inc. (KPLT): Results of Operations and Financial Condition

Katapult Holdings, Inc. (KPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Ex. 99.1 Katapult Reports Second Quarter Results Gross Originations Increase 5% , 15th Consecutive Quarter of Growth Revenue Grows 4% ; Adjusted EBITDA Increases Nearly 280% Pending Merger Transaction with The Aaron’s Company and CCF Holdings LLC Expected to Create a Scaled Finan

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.